Regent Peak Wealth Advisors LLC Acquires 97 Shares of Abbott Laboratories (NYSE:ABT)

Regent Peak Wealth Advisors LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.0% in the 4th quarter, Holdings Channel reports. The firm owned 4,873 shares of the healthcare product maker’s stock after purchasing an additional 97 shares during the quarter. Regent Peak Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $551,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Future Financial Wealth Managment LLC bought a new stake in Abbott Laboratories in the third quarter valued at approximately $31,000. Peterson Financial Group Inc. acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $32,000. Valued Wealth Advisors LLC boosted its stake in shares of Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after purchasing an additional 127 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Abbott Laboratories during the second quarter worth $32,000. Finally, Highline Wealth Partners LLC acquired a new position in Abbott Laboratories in the third quarter valued at $37,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Oppenheimer started coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective on the stock. Evercore ISI lifted their price objective on shares of Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Mizuho raised their price target on shares of Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a report on Thursday, October 17th. Jefferies Financial Group upped their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a report on Thursday, October 17th. Finally, Piper Sandler Companies started coverage on Abbott Laboratories in a research note on Thursday, September 19th. They set an “overweight” rating and a $131.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $131.57.

Abbott Laboratories Stock Up 0.8 %

ABT stock traded up $0.93 during trading on Tuesday, reaching $113.97. The stock had a trading volume of 2,385,787 shares, compared to its average volume of 4,094,731. The company has a market capitalization of $197.68 billion, a price-to-earnings ratio of 34.64, a P/E/G ratio of 2.69 and a beta of 0.73. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average is $115.44 and its two-hundred day moving average is $112.31. Abbott Laboratories has a one year low of $99.71 and a one year high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 EPS. Equities research analysts forecast that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 annualized dividend and a yield of 2.07%. Abbott Laboratories’s dividend payout ratio is presently 71.73%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.